Cue Biopharma (NASDAQ:CUE) Shares Gap Down - Here's Why

robot
Abstract generation in progress

Cue Biopharma (NASDAQ:CUE) experienced a significant gap down in its stock price, opening at $11.06 after closing at $16.6260, and later trading at $15.5140. Despite a recent “Buy” rating from Wall Street Zen, the overall analyst sentiment averages to a “Sell,” reflecting the company’s unprofitability with negative net margin and ROE, alongside a negative P/E ratio. The clinical-stage biotechnology firm, which is developing a Cytokine Release & Targeting (CRT) platform, reported quarterly EPS of $0.30 and revenue of $21.94 million.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin